Key Takeaways
- • Baylor College of Medicine has launched BCM Legacy Fund I, a venture capital fund backing early-stage biotech startups, funded by philanthropic capital from private foundations and donor-advised funds.
- • The fund's first investment is an undisclosed amount in Houston-based Nemea Therapeutics, a Baylor and Germany's Lead Discovery Center spinout developing an oral drug for metastatic triple-negative breast cancer.
- • The fund expects to invest in about 15 early-stage startups over five years; Baylor declined to disclose the fund's total size.
- • Managing partner Burton Hanson and investor Steve Lehmann oversee the fund, with the Greater Houston Community Foundation as philanthropic partner.
- • The fund uses institutional innovation mapping and AI-enhanced due diligence to source and vet targets.
Summary
Houston's Baylor College of Medicine has unveiled BCM Legacy Fund I, a venture capital vehicle designed to bridge the funding gap between academic research and private investment for early-stage biotech companies. According to the original report from InnovationMap, the fund has already made its first investment, an undisclosed amount in Nemea Therapeutics, a Houston biotech spun out of Baylor and Germany's Lead Discovery Center.
Nemea is developing an oral drug for metastatic triple-negative breast cancer that no longer responds to currently available therapies. The report cites estimates of roughly 38,000 to 57,000 Americans diagnosed annually with this condition, and one study showing about half of patients surviving past one year after diagnosis. Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor, and last year said it was seeking $25 million to $30 million in seed and Series A funding. The company plans to begin clinical trials next year in collaboration with Baylor's Lester and Sue Smith Breast Center.
Baylor President, CEO and Executive Dean Dr. Jakub Tolar said in a press release that many laboratory discoveries "stall where academic funding ends and private investment has not yet begun." The college noted that the National Institutes of Health awards more than $36 billion annually for biomedical research, yet some discoveries never advance because they do not fit venture capital economics.
The fund aggregates philanthropic capital from private foundations and donor-advised funds and invests so startups can progress to later-stage rounds. The Greater Houston Community Foundation is its philanthropic partner. Burton Hanson, a Houston entrepreneur and investor, serves as managing partner, overseeing the fund alongside Chicago investor Steve Lehmann, who previously led the University of Chicago's Innovation Fund. The governing board includes Debra McCoy, former BlackRock managing director and Bain partner, and Paul Thomas, co-founder and CEO of Luscinia Health. Dr. Paul Klotman, former Baylor president, is a senior strategic adviser.
The fund expects to back about 15 early-stage companies over five years. Sourcing relies on what the fund calls high-resolution innovation maps of research institutions, which identify emerging researchers and link Baylor's research output to biotech demand, along with AI agents that assist due diligence. Baylor did not disclose the fund's size or the amount invested in Nemea.
Nemea is developing an oral drug for metastatic triple-negative breast cancer that no longer responds to currently available therapies. The report cites estimates of roughly 38,000 to 57,000 Americans diagnosed annually with this condition, and one study showing about half of patients surviving past one year after diagnosis. Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor, and last year said it was seeking $25 million to $30 million in seed and Series A funding. The company plans to begin clinical trials next year in collaboration with Baylor's Lester and Sue Smith Breast Center.
Baylor President, CEO and Executive Dean Dr. Jakub Tolar said in a press release that many laboratory discoveries "stall where academic funding ends and private investment has not yet begun." The college noted that the National Institutes of Health awards more than $36 billion annually for biomedical research, yet some discoveries never advance because they do not fit venture capital economics.
The fund aggregates philanthropic capital from private foundations and donor-advised funds and invests so startups can progress to later-stage rounds. The Greater Houston Community Foundation is its philanthropic partner. Burton Hanson, a Houston entrepreneur and investor, serves as managing partner, overseeing the fund alongside Chicago investor Steve Lehmann, who previously led the University of Chicago's Innovation Fund. The governing board includes Debra McCoy, former BlackRock managing director and Bain partner, and Paul Thomas, co-founder and CEO of Luscinia Health. Dr. Paul Klotman, former Baylor president, is a senior strategic adviser.
The fund expects to back about 15 early-stage companies over five years. Sourcing relies on what the fund calls high-resolution innovation maps of research institutions, which identify emerging researchers and link Baylor's research output to biotech demand, along with AI agents that assist due diligence. Baylor did not disclose the fund's size or the amount invested in Nemea.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.